Verition Fund Management
NRIX icon

Verition Fund Management’s Nurix Therapeutics NRIX Stock Holding History

Verition Fund Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$738K Buy
+30,405
New +$518K ﹤0.01% 1536
2026
Q1 		– Sell
-68,754
Closed -$1.3M – 3144
2025
Q4 		$1.3M Buy
+68,754
New +$988K 0.01% 1948
2025
Q3 		– Sell
-41,922
Closed -$477K – 3931
2025
Q2 		$477K Buy
+41,922
New +$453K ﹤0.01% 2968
2025
Q1 		– Sell
-31,396
Closed -$592K – 3590
2024
Q4 		$592K Buy
+31,396
New +$720K ﹤0.01% 2374
2024
Q2 		– Sell
-13,175
Closed -$194K – 3179
2024
Q1 		$194K Buy
+13,175
New +$142K ﹤0.01% 2506

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verition Fund Management's NRIX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 30,405 shares worth $738K. The stake represents ﹤0.01% of the portfolio and ranks #1536 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in NRIX as recently as Q4 2025.

Verition Fund Management first reported a position in NRIX in Q1 2024 and has held it in 5 quarters since. The position peaked at $1.3M in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Verition Fund Management held 30,405 shares of Nurix Therapeutics worth $738K as of Q2 2026.
  • Nurix Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1536 holding.
  • Verition Fund Management first reported a position in Nurix Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Verition Fund Management's Nurix Therapeutics position peaked at $1.3M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.